ADPT: Bullish Pennant detected on 6 May 2026

ADPT is forming a bullish pennant after a sharp three-month decline of 25.51%. The pattern shows solid structure (13.0/15) with the stock consolidating between support at $12.36 and resistance at $15.61, currently trading at $13.78. Volume scores a strong 12.0/12, with today's 3.13M shares traded representing a 1.92x volume multiple above the 20-day average—critical for pennant confirmation. The breakout score of 13.0/13 and overall score of 77.0/98 suggest a technically sound setup. RSI at 46.65 is neutral, neither overbought nor oversold, positioning well for an upside move. The stock sits 64.54% above its 52-week low, indicating recovery momentum from depressed levels.

Adaptive Biotechnologies is a Seattle-based immunotherapy company focused on T-cell receptor sequencing and clonal diversity analysis. The biotech sector remains under pressure—the Health Care sector regime shows a bearish regime score of -0.0, reflecting broader biotech headwinds around FDA approvals and funding tightness. Recent biotech volatility has weighed on ADPT's valuation. The stock's 33.62% discount to its 52-week high reflects sector-wide selloffs rather than company-specific catastrophe. No major catalyst announcements have emerged in recent weeks to explain the immediate three-month decline, suggesting this consolidation may represent exhausted selling pressure. The bullish market regime (score 0.86) provides macro tailwind for reversal patterns, even as biotech faces structural challenges.

A successful breakout above $15.61 resistance would target $14.81 conservatively (measured move calculation), with potential for continuation toward the 52-week highs. Volume confirmation is critical—breakout requires sustained volume above 1.6M shares daily to validate the pennant resolution. The pattern's 61.23% win probability suggests better-than-coin-flip odds, though this is not dominant conviction. Invalidation occurs decisively below $12.36 support, where the lower pennant boundary breaks and the consolidation fails. This would signal sellers retained control and the three-month decline resumes. Traders should watch for volume expansion on any breakout attempt; weak breakouts (low volume) tend to reverse quickly in pennant setups.

Several risks warrant caution. The Health Care sector regime is bearish (score -0.0), creating headwinds even for bullish technical patterns—sector rotation could overwhelm stock-specific setups. ATR volatility of 5.01% is moderate-to-elevated, and beta of 1.13 means ADPT amplifies broader market swings. Recent two-week and one-month returns are negative despite technical stabilization, suggesting weak underlying momentum. A potential unknown risk: no recent earnings date or major news catalyst surfaced in searches, raising questions about what fundamental developments justify a reversal. If earnings disappointment or clinical trial setback emerges, the pattern breaks immediately. The stock remains 33% below 52-week highs, and short interest or insider selling would be material red flags not visible in technical data alone. Biotech funding environment remains constrained.